Drawing for HISTIDE INSIDE

USPTO serial 79167812

HISTIDE INSIDE

Reviewed by CopyMark Law Group

Reg. 4970965Status 404
Filing date
Status date
Registration date
Jun 7, 2016
Examiner
PARKS, KIMBERLY L
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with HISTIDE INSIDE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jacqueline M. Lesser

Jacqueline M. Lesser Baker & Hostetler LLP2929 Arch StreetCira Centre, 12th FloorPhiladelphia, PA 19104-2891

Goods and services

ClassDescriptionStatusFirst use
001Stem cells for scientific use; chemical products for biotechnological product development; proteins in raw material form for scientific use; chemical products for the purification of proteins for in-vitro use; synthetic peptides for the manufacture of cosmetics; stem cells other than for medical or veterinary useSECTION 71 - CANCELLED—
003Cosmetics; cosmetic products for skin appearance care; cosmetic preparations for skin regeneration; non-medicated anti-aging skin care preparations; gels, lotions, non-medicated serums, creams and non-medicated general purpose ointments for cosmetic use; cosmetic preparations for hair restoration; hair lotionsSECTION 71 - CANCELLED—
005Pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; pharmaceutical preparations for the treatment of bone diseases, for cartilaginous diseases, for vascular diseases, for neuronal degeneration, for degeneration of tendons and ligaments, for retinal degeneration, for renal degeneration, degeneration of soft tissue, for diseases with abnormal cell proliferation; natural biomaterials for bone filling for medical purposes; natural biomaterials for filling cartilage for medical purposes; stem cells for medical use; surgical implants comprising living tissues; surgical dressings in the form of cloths; surgical implants comprising living tissue grown from stem cells; synthesized peptides and polynucleotides (DNAs, RNAs) for pharmaceutical use for the treatment of tissue, whether relating to human or animal tissue, bone diseases, cartilaginous diseases, vascular diseases, neuronal degeneration, degeneration of tendons and ligaments, retinal degeneration, renal degeneration, degeneration of soft tissue, diseases with abnormal cell proliferation; nucleotide and amino acid preparations for medical use; biological tissue cultures for medical useSECTION 71 - CANCELLED—
010Surgical apparatus and instruments; prostheses, namely, orthopedic prostheses, artificial joints, jaw or facial prostheses, tendon and ligament prostheses, bone prostheses, artificial bone screws, dental prostheses, vascular prostheses, heart pacemakers, artificial heart valves, breast prostheses, penile prostheses; artificial implants, namely, artificial orthopedic implants, joints, jaw or facial implants, tendon and ligament implants, skin implants, bone implants, dental implants, vascular implants, breast implants, penile implants, nerve growth implants, intraocular implants; bone substitutes for surgical use; injectors for medical use, namely, medical fluid injectors; trocarsSECTION 71 - CANCELLED—
042Technical consultancy in the field of scientific and industrial research; research and development of new products for others; research and development in the field of biotechnology; research and development for the pharmaceutical industry; research and development in the field of cosmetics; biological research services; chemical research services; scientific research services in the field of amino acids, proteins and cells; scientific laboratory services; chemistry services, namely, chemistry consultation; conducting clinical trials for others; engineering services, namely, technical project studies; engineering; chemical analysis; engineering surveyingSECTION 71 - CANCELLED—
045Intellectual property licensing; on-line social networking servicesSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 10, 2025DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Oct 10, 2025DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 2, 2023INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Sep 14, 2023INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Sep 14, 2023INPCINVALIDATION PROCESSED—
Aug 23, 2023INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Dec 23, 2022C71TCANCELLED SECTION 71—
Jun 7, 2021REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 2, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Sep 14, 2016FICSFINAL DISPOSITION NOTICE SENT TO IB—
Sep 14, 2016FIMPFINAL DISPOSITION PROCESSED—
Sep 7, 2016FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 7, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 22, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 22, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 18, 2016GPNXNOTIFICATION PROCESSED BY IB—
Mar 2, 2016OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 2, 2016OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 2, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 6, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 6, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Feb 6, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 6, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 6, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 6, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 5, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 5, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 22, 2015ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 22, 2015REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 27, 2015NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 24, 2015RFNTREFUSAL PROCESSED BY IB—
Jul 6, 2015RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 6, 2015RFRRREFUSAL PROCESSED BY MPU—
Jul 3, 2015RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 2, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 1, 2015MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 27, 2015DOCKASSIGNED TO EXAMINER—
Jun 27, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 25, 2015REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance